Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
superoxide dismutase 3 mRNA
- Development stage
- Preclinical
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Inhalation, Intracardiac
01
Overview
Superoxide dismutase 3 (SOD3) mRNA is an mRNA-based therapeutic designed to induce the expression of the extracellular superoxide dismutase enzyme. SOD3 is a key antioxidant enzyme that localizes to the extracellular matrix, where it catalyzes the dismutation of superoxide radicals into hydrogen peroxide and oxygen. By delivering the genetic instructions for SOD3 via mRNA, typically encapsulated in lipid nanoparticles (LNPs), the therapy aims to restore antioxidant capacity in tissues under high oxidative stress. This approach is primarily being investigated for cardiovascular and pulmonary conditions, such as heart failure, ischemic heart disease, and inflammatory lung diseases like acute lung injury or idiopathic pulmonary fibrosis. The goal is to mitigate the tissue damage, fibrosis, and inflammation driven by excessive reactive oxygen species (ROS).
- Other names
- EC-SOD mRNAextracellular superoxide dismutase mRNASOD3 mRNASOD-3 mRNASOD 3 mRNA
02
Targets
Ribosome
Beyond the preview
Go deeper on superoxide dismutase 3 mRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on superoxide dismutase 3 mRNA.